Risk factors of dyspeptic syndrome in patients staying in a tuberculosis in-patient unit and the state of intestinal microflora of patients before the start of anti-tuberculosis therapy
https://doi.org/10.21292/2075-1230-2022-100-4-46-51
Abstract
The article describes risk factors for the development of intestinal indigestion syndrome (IIS) in 109 patients with tuberculosis while they were receiving anti-tuberculosis chemotherapy (ATCT) and the results of assessment of the intestinal microbial population in 30 patients with tuberculosis before chemotherapy start. The following factors made significant contribution to development of intestinal indigestion syndrome: HIV infection, the number of doses of anti-tuberculosis drugs taken, and chronic gastrointestinal diseases. Even before the start of chemotherapy, the patients had disorders of the intestinal microflora, which were characterized by a decrease in the quantity of obligate bacteria, and higher frequency and number of facultative and transient bacteria.
About the Authors
А. А. Kholodov
Kemerovo State Medical University
Russian Federation
Russian Federation
Artem A. Kholodov, Resident Physician of Phthisiology Department
22A, Voroshilova St., Kemerovo, 650029
Phone: 384-2-54-56-51
Yu. V. Zakharova
Kemerovo State Medical University
Russian Federation
Russian Federation
Yulia V. Zakharova, Doctor of Medical Sciences, Associate Professor, Associate Professor of Microbiology, Immunology and Virology Department
22A, Voroshilova St., Kemerovo, 650029
Phone: 384-2-73-28-71
L. Yu. Otdushkina
Kemerovo State Medical University
Russian Federation
Russian Federation
Larisa Yu. Otdushkina, Assistant of Microbiology, Immunology and Virology Department
22A, Voroshilova St., Kemerovo, 650029
Phone: 384-2-73-28-71
T. V. Pyanzova
Kemerovo State Medical University
Russian Federation
Russian Federation
Tatiana V. Pyanzova, Candidate of Medical Sciences, Associate Professor, Head of Phthisiology Department
22A, Voroshilova St., Kemerovo, 650029
Phone: 384-2-54-56-51
References
1. Degtyareva S.Yu., Beloborodova E.N., Pokrovskaya А.V., Klimova Yu.А., Viktorova I.B., Zimina V.N. The safety of treatment of multiple drug resistant tuberculosis in HIV positive patients receiving antiretroviral therapy. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 3, pp. 46-53. (In Russ.)
2. Zimina V.N., Vasilyeva I.А., Batyrov F.А., Samoylova А.G. The efficacy of surgical treatment of patients with TB/HIV co-infection. Tuberculosis and Lung Diseases, 2013, vol. 90, no. 3, pp. 15-21. (In Russ.)
3. Levanova L.А. Mikroekologiya kishechnika cheloveka, korrektsiya mikroflory pri disbioticheskikh sostoyaniyakh. Diss. dokt. med. nauk. [Microbial ecology of the Western Siberia intestine, management of bacterial population in case of dysbiosis. Doct. Diss.]. Moscow, 2003. 289 p.
4. Lineva Z.E. et al. Clinical and bacteriological manifestations of intestinal dysbiosis in patients with pulmonary tuberculosis complicated by contaminant diseases of the gastrointestinal tract. Mezhdunarodny Journal Prikladnykh i Fundamentalnykh Issledovaniy, 2013, no. 12, pp. 88-93. (In Russ.)
5. Mordyk А.V., Sitnikova S.V., Puzyreva L.V., Nazarova O.I., Fursevich L.N. Evaluation of the manifestations of HIV infection and the results of treatment of patients with tuberculosis in a specialized hospital. VICH-Infektsiya i Immunosupressii, 2015, vol. 7, no. 1, pp. 69-75. (In Russ.)
6. The Edict On Approval of the Industry Standard for Protocol of Patient Management. Intestinal dysbacteriosis. Order No. 231 as of June 09, 2003 by the Ministry of Health of the Russian Federation. (In Russ.)
7. Puzanov V.А., Komissarova O.G., Nikonenko B.V. Bacterial microbiota of lower gut and bronchi in tuberculosis patients. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 5, pp. 37-43. (In Russ.)
8. Rodina O.V., Borisov S.E., Ivanova D.А. Adverse reactions to various regimens of chemotherapy in respiratory tuberculosis patients. Tuberkulez i Sotsialno-Znachimye Zabolevaniya, 2020, no. 2, pp. 44-54. (In Russ.)
9. Federalnye klinicheskiye rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya s mnozhestvennoy i shirokoy lekarstennoy ustoichivostyu vozbuditelya. [Federal clinical guidelines for diagnosis and treatment of respiratory tuberculosis with multiple and extensive drug resistance]. Moscow, Tver, Triada Publ., 2014. 72 p.
10. Khasanova G.R. et al. Changes of intestinal microbiota in patients with HIV. Kazanskiy Meditsinskiy Journal, 2013, vol. 94, no. 1. (In Russ.)
11. Brust J.C.M., Shah N.S., van der Merwe T.L. et al. Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa. J. Acquired Imm. Def. Syndrom, 2013, vol. 4, no. 62, pp. 436-440.
12. Dumas A., Corral D., Colom A., Levillain F., Peixoto A., Hudrisier D., Poquet Y., Neyrolles O. The host microbiota contributes to early protection against lung colonization by Mycobacterium tuberculosis. Front Immunol., 2018, no. 9, pp. 26-56.
13. Eribo O.A., du Plessis N., Ozturk M. et al. The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty? Cell. Mol. Life Sci., 2020, no. 77, pp. 1497-1509.
14. Honda K., Littman D.R. The microbiota in adaptive immune homeostasis and disease. Nature, 2016, no. 535 (7610), pp. 75.
15. Huerga H., Bastard M., Kamene M. et al. Outcomes from the first multidrug-resistant tuberculosis programme in Kenya. Int. J. Tuberc. Lung Dis., 2017, vol. 3, no. 21, pp. 314-319.
16. Isaakidis P., Varghese B., Mansoor H. et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS ONE, 2012, vol. 7, no. 7, pp. e40781. doi: 10.1371/journal.Pone.0040781.
17. Khan N., Mendonca L., Dhariwal A., Fontes G., Menzies D., Xia J., Divangahi M., King I.L. (2019) Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis. Mucosal Immunol., 2017, vol. 12, no. 3, pp. 772.
18. O’Donnell M.R., Padayatchi N., Kvasnovsky C. et al. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg. Infect. Dis., 2013, vol. 3, no. 19, pp. 416-424.
19. Sagwa E., Ruswa N., Musasa J.P. et al. Adverse events during treatment of drug-resistant tuberculosis: Acomparison between patients with or without human immunodeficiency virus co-infection. Drug Safety, vol. 11, no. 36, pp. 1087-1096.
Review
For citations:
Kholodov А.А., Zakharova Yu.V., Otdushkina L.Yu., Pyanzova T.V. Risk factors of dyspeptic syndrome in patients staying in a tuberculosis in-patient unit and the state of intestinal microflora of patients before the start of anti-tuberculosis therapy. Tuberculosis and Lung Diseases. 2022;100(4):46-51. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-4-46-51
Views:
445
Email this article 